Latest Advances in Lung Cancer Research

A new study offers hope for people with EGFR lung cancer whose treatment stopped working. Published in the New England Journal of Medicine, it found that osimertinib and savolitinib together beat chemotherapy.

Tarlatamab small cell lung cancer research just took a major step forward. A new study in the New England Journal of Medicine found that adding tarlatamab to standard maintenance treatment helped patients live much longer.

Not long ago, lung cancer had almost no organized patient advocacy and nowhere near the visibility that breast cancer or pediatric cancer communities had built. A new article in the Journal of Thoracic Oncology, co-written by four advocates and researchers — including LCFA’s own Jill Feldman — traces how that changed over the past two decades, and what’s still unfinished.

Researchers from Yale University looked at more than 28,000 older adults with early-stage non-small cell lung cancer. They found that Black patients were 8 to 9 percentage points less likely than White patients to receive curative treatment.

Lung cancer kills more people than breast, colon, and cervical cancers combined. Yet it is the cancer we screen for the least. A new study in the Journal of the American Medical Association shows that universal lung cancer screening could change this.

The Lung Cancer Genetics Study aims to understand genetic factors in lung cancer, improving detection, risk reduction, and care through a collaborative research effort.

Lung cancer stigma negatively impacts the clinical care and outcomes of those diagnosed, resulting in enduring disparities.